A new and potent calmodulin antagonist, HF-2035, which inhibits vascular relaxation induced by nitric oxide synthase

European Journal of Pharmacology

Volumn 299, Issue 1-3, 1996, Pages 119-126

  Win, Nang Hla Hla ^a   Ishikawa, Tomohiko ^a   Saito, Nozomi ^a   Kato, Masumi ^a   Yokokura, Hisayuki ^a   Watanabe, Yasuo ^a   Iida, Yuji ^a   Hidaka, Hiroyoshi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calmodulin antagonist; HF 2035; Nitric oxide (NO) synthase inhibitor; Vascular relaxation; W 7

Indexed keywords

ACETYLCHOLINE; AMINOGUANIDINE; ARGININE; CALCIMYCIN; CALMODULIN; CALMODULIN INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HF 2035; MYOSIN LIGHT CHAIN KINASE; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; N MORPHOLINO N NITROSAMINOACETONITRILE; NEW DRUG; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE (CALCIUM,CALMODULIN) II; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; CAROTID ARTERY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PURIFICATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SMOOTH MUSCLE RELAXATION; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0029995110     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00844-6     Document Type: Article

References (30)

1. G-monomethyl-L-arginine on endotoxin-induced alterations of vascular reactivity, Life Sci. 48, 189.
2. 2+ signaling pathways, Science 260, 181.
3. Bredt, D.S. and S. Snyder, 1990, Isolation of nitric oxide synthases, a calmodulin-requiring enzyme, Proc. Natl. Acad. Sci. USA 87, 682.
4. Förstermann, U., E.I. Closs, J.S. Pollock, M. Nakane, P. Schwarz, I. Gath and H. Kleinert, 1994, Nitric oxide synthase isozymes: characterization, purification, molecular cloning and functions, Hypertension (Dallas) 23, 1121.
5. G-nitroarginine, Biochemistry 32, 8512.
6. Hidaka, H., M. Asano, S. Iwadare, I. Matsumoto, T. Totsuka and N. Aoki, 1978, A novel vascular relaxing agent, N-(6-aminohexyl)-5-chloro-naphthalenesulfonamide which affects vascular smooth muscle actomyosin, J. Pharmacol. Exp. Ther. 207, 8.
7. Hidaka, H., M Inagaki, S. Kawamoto and Y. Sasaki, 1984, Isoquinoline sulfonamides, novel and potent inhibitors of cyclic nucleotide-dependent protein kinase and protein kinase C, Biochemistry 23, 5036.
8. Ignarro, L.J., 1991, Signal transduction mechanisms involving nitric oxide, Biochem. Pharmacol. 41, 485.
9. Illiano, S., T. Nagao and P.M. Vanhoutte, 1992, Calmidazolium, a calmodulin inhibitor, inhibits endothelium-dependent relaxations resistant to nitro-L-arginine in the canine coronary artery, Br. J. Pharmacol. 107, 387.
10. Kemp, B.E., R.B. Pearson, V. Guerriero, Jr., I.C. Bagchi and A.R. Means, 1987, The calmodulin-binding domain of chicken smooth muscle myosin light chain kinase contains a pseudosubstrate sequence, J. Biol. Chem. 262, 2542.
11. Klee, C.B. and T.C. Vanaman, 1982, Calmodulin, Adv. Protein Chem. 35, 213.
12. Klee, C.B., T.H. Crouch and P.G. Richmann, 1980, Calmodulin, Annu. Rev. Biochem. 49, 489.
13. Lowenstein, C.J. and S.H. Snyder, 1992, Nitric oxide, a novel biologic messenger, Cell 70, 705.
14. G-nitro-L-arginine, FEBS Lett. 332, 203.
15. Misko, T.P., W.M. Moore, T.P. Kasten, G.A. Nickols, J.A. Corbett, R.G. Tilton, M.L. McDaniel, J.R. Williamson and M.G. Currie, 1993, Selective inhibition of the inducible nitric oxide synthase by aminoguanidine, Eur. J. Pharmacol. 233, 119.
16. Moncada, S. and A, Higgs, 1993, The L-arginine-nitric oxide pathway, New Engl. J. Med. 329, 2002.
17. Moncada, S., R.M. Palmer and E.A. Higgs, 1991, Nitric oxide: physiology, pathology, and pharmacology, Pharmacol. Rev. 43, 109.
18. Nairn, A.C. and M.R. Picciotto, 1994, Calcium/calmodulin-dependent protein kinases, Semin. Cancer Biol. 5, 295.
19. Narayanan, K. and O.W. Griffith, 1994, The synthesis of L-thiocitrulline, L-homothiocitrulline, and S-methyl-L-thiocitrulline: a new class of potent nitric oxide synthase inhibitors, J. Med. Chem. 37, 885.
20. Nathan, C., 1992, Nitric oxide as a secretory product of mammalian cells, FASEB J. 6, 3051.
21. 2+/calmodulin-dependent protein kinases in insulin release from the rat pancreatic β cell, Biochem. Biophys. Res. Commun. 191, 255.
22. 2+ /calmodulin-dependent protein kinase inhibitor, reversibly depresses the rate of beating of cultured fetal mouse cardiac myocytes, J. Pharmacol. Exp. Ther. 270, 1319.
23. G-cyclopropyl-L-arginine: two novel inhibitors of macrophage nitric oxide synthase, J. Med. Chem. 35, 1137.
24. G-Methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase, Biochemistry 32, 9677.
25. Stamler, J.S., D.J. Singel and J. Loscalzo, 1992, Biochemistry of nitric oxide and its redox-activated form, Science 258, 1898.
26. 2+ regulation, Prog. Neurobiol. 29, 321.
27. 2+ /calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells, Biochem, Biophys. Res. Commun. 181, 968.
28. 2+ /calmodulin-dependent protein kinase II, J. Biol. Chem. 265, 4315.
29. 2+ /calmodulin-dependent protein kinase II, KN62, inhibits cholinergic-stimulated parietal cell secretion, Am. Physiol. Soc. 262, G118.
30. Yokokura, H., M.R. Picciotto, A.C. Nairn and H. Hidaka, 1995, The regulatory region of calcium/calmodulin-dependent protein kinase I contains closely associated autoinhibitory and calmodulin-binding domains, J. Biol. Chem. 270, 23851.